glp·helper
glphelper.com/ozempic/california/la-mesa
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in La Mesa, CA

Verified Ozempic providers in La Mesa, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
30
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
31 of 31 shown

Find an Ozempic provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /ozempic/california/{city}
§ 03Getting Ozempic in La Mesa
31 providers · La Mesa, CA

How to get Ozempic in La Mesa.

31 GLP-1 prescribers and 7 local resource types are on record for La Mesa, plus 3 nearby towns in the directory.

Prescribers in La Mesa
31 prescribers
31 GLP-1 prescribers in La Mesa, most listed as Family Medicine (14), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (5). Any California-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are El Cajon (27 providers), San Diego (44 providers) and Chula Vista (29 providers).
Around the prescription in La Mesa
7 listed nearby
20 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near La Mesa.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in La Mesa

La Mesa, California has a population of 61,121 people. The adult obesity rate in La Mesa is an age-adjusted estimate of 26.4%, 2.7 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 8.8% of adults in La Mesa. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 19% of adults in La Mesa.

of La Mesa adults have obesity
26.4%
diagnosed diabetes
8.8%
no regular physical activity
19%

Age-adjusted estimates for La Mesa, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Ozempic in La Mesa
6 dietitians

The prescription is one part. Here is the rest, in La Mesa.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near La Mesa, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Jacqueline Acosta, RDN
RD
Registered dietitian
1809 National Ave
Call 619-515-2300NPI 1659135879
Nancy Alexander-Wadel, RD, CDE
RD
Registered dietitian
751 Medical Center Ct
Call 619-482-5938NPI 1700913936
Diane Bloomberg, MS, RDN, CNSC
RD
Registered dietitian
5555 Grossmont Center Dr
Call 619-300-5340NPI 1336601053
Danielle Gaffen, MS, RDN, LD
RD
Registered dietitian
4116 Morning Star Ct
Call 619-985-5656NPI 1154905727
Natasha Godwin, RDN
RD
Registered dietitian
9320 Earl St Unit 15
Call 858-382-3410NPI 1952978306
Sasha Hetman, RD
RD
Registered dietitian
3853 Rosecrans St
Call 619-692-8229NPI 1851071401

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Lani Morales
NUTRITIONIST
Nutritionist
10990 San Diego Mission Rd
Call 619-641-4224NPI 1154105419
Amberly Rowland, MS
NUTRITIONIST
Nutritionist
8330 Allison Ave
Call 619-540-0558NPI 1063910271
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in California

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]